Loading organizations...
§ Private Profile · Paris, France
Biotech company developing targeted gene therapies for neurodegenerative and ocular diseases using its ALIGATER™ platform.
Coave Therapeutics is a biotechnology company based in Paris, France, that develops targeted gene therapies for neurodegenerative and ocular diseases. The organization utilizes its proprietary ALIGATER platform to conjugate ligands to AAV capsids and lipid nanoparticles, aiming to improve the delivery and efficacy of genetic medicines. Its clinical pipeline focuses on transitioning treatments from rare to prevalent conditions, highlighted by its lead program, CoTx-101, which targets retinal vascular diseases such as neovascular macular degeneration. The enterprise is backed by a syndicate of international life science venture capital firms and strategic investors, including Seroba Life Sciences, Omnes Capital, Kurma Partners, and Théa Open Innovation. In April 2024, the company expanded its operations into the United States. The exact founding year and original founders remain undisclosed, though the company originated from scientific research at the University of Nantes.
Coave Therapeutics has raised $94.8M across 5 funding rounds.
Coave Therapeutics has raised $94.8M in total across 5 funding rounds.
Coave Therapeutics has raised $94.8M across 5 funding rounds. Most recently, it raised $33.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $33M Series A | Bpifrance, Novo Holdings | High Tech Gründerfonds, Kurma Partners, Pontifax Venture Capital | Announced |
| Feb 29, 2024 | $2.9M Grant | ALS Association | — | Announced |
| Sep 16, 2021 | $11.8M Venture Round | TH | — | Announced |
| Jul 21, 2021 | $25M Series B Plus | Seroba Life Sciences | — | Announced |
| Nov 1, 2017 | $22M Series B | — | High Tech Gründerfonds, Kurma Partners, Pontifax Venture Capital | Announced |
Coave Therapeutics has raised $94.8M in total across 5 funding rounds.
Coave Therapeutics's investors include Bpifrance, Novo Holdings, High-Tech Gründerfonds, Kurma Partners, Pontifax Venture Capital, ALS Association, Th, Seroba Life Sciences.
Coave Therapeutics is a clinical-stage biotechnology company developing targeted gene therapies for rare ocular and central nervous system (CNS) diseases.[1][2][4] It pioneers the ALIGATER™ platform, which uses ligand-conjugated AAV vectors for precise, tissue-specific delivery that is safer and more effective than traditional methods, starting with ophthalmology and expanding to CNS and neuromuscular indications.[2][3] The company serves patients with unmet needs in retinal vascular diseases like nAMD and DME, offering durable treatments like lead program CoTx-101 to reduce frequent injections.[2] Backed by top life science investors, Coave has raised over €65 million across Series A and B rounds, fueling pipeline advancement toward clinical trials.[3][5]
Coave Therapeutics, formerly Horama, emerged from innovations in gene therapy delivery and rebranded to reflect its focus on precision vectors.[1][5] Founded before 2021 (with Series B in July 2021), it is led by CEO Rodolphe Clerval, who has guided fundraising and platform development.[3][5] The idea stemmed from solving gene therapy's delivery challenges, particularly for extra-hepatic tissues, leading to the ALIGATER™ platform of AAV-ligand conjugates.[2][3][5] Early traction included a €33.1 million Series B in 2021 from investors like Seroba Life Sciences and Théa Open Innovation, validating its pipeline for rare ocular and CNS diseases, followed by a €32 million Series A in January 2025 co-led by Novo Holdings and Bpifrance.[3][5]
Coave rides the gene therapy revolution, addressing delivery limitations that hinder treatments for non-liver tissues amid rising demand for CNS, neuromuscular, and ocular therapies.[2][3][5] Timing aligns with maturing AAV tech and investor interest, as seen in 2025 Series A amid a push for safer, targeted vectors post-early setbacks in the field.[3] Market forces like unmet needs in rare diseases (e.g., retinal vascular conditions) and pharma partnerships favor its platform, which influences the ecosystem by enabling broader gene therapy applications and collaborations.[2][3] Headquartered in Paris with labs nearby, it bolsters Europe's biotech hub while validating suprachoroidal delivery for transformative retinal care.[2][4]
Coave is poised to nominate two candidates for CTA/IND-enabling studies in 2026, prioritizing CNS, neuromuscular, and eye programs with ALIGATER™ expansion.[3] Trends like precision medicine and manufacturing efficiencies will accelerate its pipeline, potentially yielding first-in-class therapies and pharma deals. Its influence may grow through board additions (e.g., Novo Holdings, Bpifrance) and platform licensing, redefining gene therapy delivery from ophthalmology outward—positioning Coave as a leader in life-changing genetic medicines for rare diseases.[2][3]